H.C. Wainwright raised the firm’s price target on Solid Biosciences to $16 from $9 and keeps a Buy rating on the shares after the compony entered into a non-exclusive worldwide license and collaboration agreement with Armatus Bio for the use of AAV-SLB101. The analyst expects Solid Bio to enter into additional non-exclusive partnerships for the use of its capsid libraries to bring in non-dilutive funding to support its proprietary pipeline development.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLDB:
- SLDB Upcoming Earnings Report: What to Expect?
- Solid Biosciences announces licensing agreement with Armatus Bio
- Solid Biosciences files to sell 19.685M shares of common stock for holders
- Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
- Solid Biosciences granted FDA ODD for SGT-003
